z-logo
Premium
P2‐341: A robotic screen of a small‐molecule chemical library for inhibitors of Aβ oligomer formation
Author(s) -
LeVine Harry,
Augelli-Szafran Corinne E.,
Voss Randal S.,
Walker John A.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1418
Subject(s) - oligomer , chemistry , drug discovery , small molecule , monomer , combinatorial chemistry , biotinylation , peptide , biophysics , biochemistry , organic chemistry , biology , polymer
C-terminus of A 40, was administered to 5-month-old plaque-bearing APPxPS1 mice (Swedish mutation of APP, E9 mutation of PS1). Brain, CSF, and plasma were harvested 5 days following a single intraperitoneal injection of vehicle or 0.1-10 mg/kg PF-4360365 to determine the effect on A levels. Results: A 1-X, 1-40, and 1-42 were not significantly reduced in cortex. In hippocampus, all three A fragments were significantly reduced to varying degrees, although no dose-response relationship was observed. A 1-X levels in CSF were significantly elevated at the 10 mg/kg dose; no other significant changes were detected. Assaying samples revealed up to 10,000% increase in plasma A 1-X but only up to 35% change in A 1-40 due to interference of the therapeutic antibody with A 1-40 detection. Samples were extracted with guanidine and antibodies were removed using solid-phase extraction (SPE). Following this clean-up step, A 1-40 levels correlated with A 1-X levels. A 1-42 levels in plasma appeared to be reduced by up to 50% before SPE and increased by up to 300% following SPE. However, using synthetic A standards in solution or spiked into plasma, it was discovered that excess A 1-40 concentrations can increase the apparent A 1-42 signal with the polyclonal antibodies being used to measure A 42. When a proprietary monoclonal A 42selective monoclonal antibody was used to capture A 42, no change in plasma A 42 levels were observed after PF-4360365 treatment. Therapeutic antibody concentrations in plasma significantly correlated to A 1-X and A 1-40 in plasma, but not to any A fragment in CSF or brain. No inter-compartmental correlation was observed for A levels in vehicle or antibody-treated mice. Conclusions: A single injection of PF-4360365 showed selective mobilization of A in the CNS, accompanied by robust elevation of A 40 in novel A assays following denaturation and chromatographic separation of the antigen-antibody complex.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom